Noninvasive Biomarker Testing and Risk Stratification in MASLD/MASH: Laboratory Options for Assessing Risk of Liver Fibrosis
Tracking # 20-1375929
Price not reported
There are no ratings for this course
Learn moreCourse overview
This webinar will examine the increasing prevalence of MASLD and MASH in the United States and the challenges that often lead to delayed and missed diagnoses. Attendees will gain insights into the evolving role of noninvasive blood-based biomarker testing for MASLD and MASH in supporting risk stratification and informing management decisions. Dr. Meena Bansal of Mount Sinai Health System will share real-world perspectives on the importance of incorporating these guideline-recommended biomarker tests into diagnostic and prognostic algorithms.
Subject areas
This course counts toward the state boards and subject areas below.
American Board of Clinical Chemistry
Clinical Chemistry Diplomate
Molecular Diagnostics Diplomate
Toxicological Chemistry Diplomate
Florida Board of Clinical Laboratory Personnel
Clinical Laboratory Director
Clinical Laboratory Supervisor
Clinical Laboratory Technician
Clinical Laboratory Technologist
Public Health Director
Public Health Supervisor
Public Health Technologist
Disclosure statements
The Association for Diagnostics & Laboratory Medicine (ADLM) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported financial relationships:
- Meena Bansal, MD, FAASLD, ABOM
- ¿Honorarium: Madrigal Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Siemens Healthineers
- Consulting Fees: The Kinetix Group, Madrigal Pharmaceuticals, Pfizer, Fibronostics, Novo Nordisk, GlaxoSmithKline (GSK), Boston Pharmaceuticals, Merck, Boehringer Ingelheim, Curve Biosciences, mBIOTA, Eli Lilly
- Grant and/or Research Support: National Institutes of Health, Centers for Disease Control and Prevention / National Institute for Occupational Safety and Health, Pfizer, The Kinetix Group, Petauri, Histoindex, Siemens Healthineers